MORF-627

Overview

MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β . MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Integrin | Products > Signaling Pathways > TGF-beta/Smad

Product Information

• Catalog No.: HY-149136
• CAS No.: 2412688-16-3
• Molecular Formula: C31H40FN3O4
• Molecular Weight: 537.67
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source